We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings PLC | AQSE:COG.GB | Aquis Stock Exchange | Ordinary Share | GB00B8DV9647 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 45.50 | 42.00 | 49.00 | 45.50 | 45.50 | 45.50 | 0.00 | 06:55:38 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2022 to May 2024
TIDMCOG
RNS Number : 8184W
Cambridge Cognition Holdings PLC
20 April 2023
Cambridge Cognition Holdings Plc
(" Cambridge Cognition" or the "Company")
Notice of Results
Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to confirm that it will announce the Company's preliminary financial results for the year ended 31 December 2022, on Wednesday 3 May 2023.
Enquiries
Cambridge Cognition Holdings Plc Tel: 012 2381 0700 Matthew Stork, Chief Executive Officer press@camcog.com Stephen Symonds, Chief Financial Officer Panmure Gordon (UK) Limited (NOMAD and Joint Broker) Tel: 020 7886 2500 Freddy Crossley / Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715 David Poutney / James Serjeant IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630 Tim Metcalfe / Graham Herring / Zach Cohen cog@investor-focus.co.uk
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORBLGDSDXBDGXC
(END) Dow Jones Newswires
April 20, 2023 02:00 ET (06:00 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
